RxDoctor Payments Data

William Boykin, MD

Urology · Ashland, KYNPI 1922077460

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,483 of the $5,328 with a category attached, or 65.4%. 26 manufacturers reported payments, led by Intuitive Surgical at 25.4% of the total.

$5,328in general payments, 2019–2025

Across 199 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Astellas Pharma US Inc$754
  • Medtronic$749
  • Pfizer$476
  • Johnson & Johnson$307
  • Endo Pharmaceuticals Inc.$267
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$1,57930%
  • Food & beverage$3,48365%
  • Education$2665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,328 in reported general payments places this provider in the 70th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$138,799
Medicare patients
445
Services billed
1,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide16$226,259
Testosterone Cypionate151$4,868
Tamsulosin Hcl261$2,733
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst76$1,287
Testosterone15$1,282
Bicalutamide19$897
Finasteride69$582
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim53$571
Alfuzosin Hcl ErAlfuzosin Hcl30$563
Levofloxacin152$504
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen119$487
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet20$331
Ciprofloxacin Hcl18$143
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$95
Cephalexin17$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$754$226,25916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 139 urology providers in Kentucky.

Other urology in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →